Cancer
Pfizer’s palbociclib most commonly used breast cancer drug in clinical trials
December 11, 2018Manufacturing and Production, Sales and Marketing Cancer, breast cancer, clinical trials, global data, oncology
Pfizer’s palbociclib is the most commonly used breast cancer drug in clinical trials, according to analytics firm GlobalData. The drug, …
AstraZeneca partners up with CRUK for new UK cancer drug discovery facility
December 10, 2018Research and Development, Sales and Marketing AstraZeneca, CRUK, Cancer, pharma
AstraZeneca is to team up with Cancer Research UK to build a new centre of excellence for accelerating the discovery …
Top Ten most popular articles on Pharmafile.com this week!
December 7, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cancer, Diagnostics, Sanofi, Takeda, brexit
Takeda’s acquisition of Shire finally got the go-ahead this week as 88% of shareholders voted in favour of French CEO …
NICE give go-ahead to Gilead’s Yescarta for adults with lymphoma
December 7, 2018Medical Communications Cancer, Cost, Gilead, NHS, NICE, Yescarta, access
The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma. Gilead’s treatment will …
AstraZeneca’s head and neck cancer treatment Imfinzi falls flat in Phase III trials
December 7, 2018Medical Communications AstraZeneca, Cancer, oncology, phase III, treatment
AstraZeneca’s immunotherapy treatment Imfinzi has failed to meet its primary goal in treating head and neck cancer in the Phase …
Amgen unveils double whammy of data for its investigational cancer immunotherapies at ASH 2018
December 5, 2018Research and Development ASH 2018, Amgen, Cancer, acute myeloid leukaemia, myeloma, pharma
Amgen has presented the first clinical data at the American Society of Hematology (ASH) Annual Meeting 2018 for two investigational …
New diagnostic test can detect any cancer type in minutes with 90% accuracy
December 5, 2018Research and Development Australia, Cancer, pharma
Researchers at the University of Queensland have a test which can rapidly detect the presence of cancer in a patient’s …
Roche’s first-line Tecentriq combo scores accelerated FDA review
December 5, 2018Research and Development ASH 2018, Cancer, Roche, lung cancer, pharma, tecentriq
Roche’s immunotherapy Tecentriq has secured Priority Review from the FDA, the company has announced, in combination with carboplatin and etoposide …
Cancer drug access for NHS patients is slowing, ICR reports
December 4, 2018Manufacturing and Production, Research and Development, Sales and Marketing Cancer, ICR, Institute of Cancer Research, NHS, NICE, UK, pharma
A new report from the Institute of Cancer Research (ICR) has indicated that NHS patients in the UK are suffering …
Gilead’s CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma
December 3, 2018Research and Development, Sales and Marketing ASH 2-18, CAR-T, Cancer, Gilead, Yescarta, leukaemia, pharma
Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the …
AbbVie’s Venclyxto combo beats standard of care in chronic lymphocytic leukaemia
December 3, 2018Research and Development, Sales and Marketing ASH 2018, AbbVie, Cancer, Venclyxto, leukaemia, pharma
AbbVie has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to reveal new data on …
Novartis unveils strong longer-term Kymriah data at ASH 2018
December 3, 2018Research and Development, Sales and Marketing ASH 2018, Cancer, Kymriah, Novartis, leukaemia, pharma
Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah (tisagenlecleucel) at the American Society of …
Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund
November 30, 2018Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, NICE, UK, melanoma, pharma
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer …
UK cervical cancer screening rates fall to 21-year low
November 28, 2018Medical Communications, Research and Development Cancer, NHS, UK, cervical cancer, pharma
A report by NHS Digital has revealed that cervical cancer screening coverage has fallen to 71.4%, down from 72% in …
European approval for Takeda’s Alunbrig in ALK+ advanced non-small cell lung cancer
November 27, 2018Research and Development, Sales and Marketing Alunbrig, Cancer, Takeda, lung cancer, pharma
Takeda’s Alunbrig (brigatinib) has been granted marketing approval by the European Commission as a monotherapy to treat anaplastic lymphoma kinase-positive …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
